Cetuximab Price in India: — Innovator, Biosimilar and Cost Per Cycle

CDSCO requires biosimilar manufacturers to demonstrate comparability to the innovator in quality, safety, and efficacy before granting approval — so the biosimilar has been reviewed against an evidence standard, not approved on trust alone. Many oncology centres in India use CDSCO-approved biosimilars routinely. If you are uncertain, ask your oncologist to explain which biosimilar is being used and why they have selected it. That is a reasonable question and your team should be able to answer it directly.

PMJAY covers a defined list of cancer treatment packages at empanelled hospitals. Whether cetuximab falls within your specific package depends on your cancer type, the protocol being used, and whether your hospital is PMJAY-empanelled for that treatment. The fastest way to get an answer is to ask the hospital's PMJAY desk or medical social worker before your first cycle — this is a routine query for them and should take very little time to resolve.

Cetuximab is a prescription biologic that requires cold-chain storage and, in most states, can only be dispensed through a hospital or authorised oncology pharmacy. Buying from an unverified source risks receiving product that has been stored incorrectly — which affects how well it works and can be dangerous. If cost is the concern, speak to your team about biosimilar options and assistance programmes. These are the safe routes to a lower bill.

The number of cycles depends on your cancer type, stage, and whether cetuximab is being given alone or alongside chemotherapy or radiotherapy. For some head and neck cancers, it is given weekly during a course of radiotherapy; for colorectal cancer, it may continue until the disease progresses or side effects require a change. Your oncologist can give you an estimated duration at your first or second appointment. Multiply that by your per-cycle cost estimate for a working total.

Coverage varies widely between policies. Many standard plans in India exclude biologics or targeted therapies outright, or impose a sub-limit that falls well short of actual cost. Check your policy document under 'exclusions', 'cancer treatment', and 'injectables or biologics'. Because cetuximab is given as day care rather than overnight admission, some day-care cancer treatment policies do include it. Contact your insurer's pre-authorisation team before your first cycle — asking after treatment has started makes approval significantly harder.

Tell your oncology team before you miss a dose, not after. Skipping cycles without warning affects your treatment outcomes and your team's planning. Most oncology centres have a medical social worker who can check PMJAY eligibility, Aarogyasri coverage, hospital financial assistance, and manufacturer access programmes on your behalf. Some charitable trusts also support cancer drug costs. Your team cannot explore options they do not know are needed — raise the concern as early as you can.